Brief: Servier And Ose Immunotherapeutics Announce Enrollment Of First Patient In Ose-127/S95011 Phase 2 Clinical Trial In Sjögren’S Syndrome

Ose Immunotherapeutics SA

25/08/2021 17:06

Aug 25 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * SERVIER AND OSE IMMUNOTHERAPEUTICS ANNOUNCE ENROLLMENT OF
FIRST
PATIENT IN OSE-127/S95011 PHASE 2 CLINICAL TRIAL IN SJÖGREN’S
SYNDROME
    * THIS INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED
PHASE 2 STUDY AIMS TO EVALUATE EFFICACY AND SAFETY OF
OSE-127/S95011 IN PATIENTS WITH SJÖGREN'S SYNDROME

Source text for Eikon:  ID:nGNX8f9vsK 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))